77th Scientific Sessions of the American Diabetes Association (ADA) 2017

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

77th Scientific Sessions of the American Diabetes Association (ADA) 2017

09 June 2017 - 13 June 2017

ODYSSEY trials reveal positive effect of alirocumab on lipid profile in patients with T2D

Roshini Claire Anthony, 20170630140300

The PCSK9* inhibitor alirocumab reduced low-density lipoprotein cholesterol (LDL-C) levels and several other lipid parameters in patients with type 2 diabetes (T2D) and high cardiovascular risk, according to two studies presented at the 77^th Scientific Sessions of the American Diabetes Association (ADA 2017) held in San Diego, California, US.

Two-way text messaging may help glycaemic control in teens with T1D

Elaine Soliven, 20170630101003

More frequent text messaging responses to reminders to check blood glucose (BG) was associated with better glycaemic control in teens with type 1 diabetes (T1D), and may help the transition from paediatric to adult care which entails greater self-care routine, suggests a study presented at the American Diabetes Association’s 77^th Scientific Sessions held in San Diego, California, US.

Glucagon-blocking drug reduces need for insulin, improves blood glucose levels in T1D patients

Audrey Abella, 20170622083649

A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.

Severe obesity linked to higher diabetes risk in children, adolescents

Elaine Soliven, 20170622063616

Severe obesity in children and adolescents may increase the risk of developing youth-onset diabetes, according to a study presented at the American Diabetes Association’s 77^th Scientific Sessions held in San Diego, California, US.

Comparable CV safety, reduced severe hypoglycaemia risk with insulin degludec vs insulin glargine

Roshini Claire Anthony, 20170621140200

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.

20170621123054

Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.

Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.

20170621122716

Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.

Podcast: Professor Bruce Neal summarizes the key findings of the Canagliflozin Cardiovascular Assessment Study.

20170621122245

Podcast: Professor Bruce Neal summarizes the key findings of the Canagliflozin Cardiovascular Assessment Study.

Podcast: Dr Carla Greenbaum speaks about the potential clinical impact of identifying individuals at risk of type 1 diabetes.

20170621121916

Podcast: Dr Carla Greenbaum speaks about the potential clinical impact of identifying individuals at risk of type 1 diabetes.

Fasting plasma glucose predicts dietary weight loss success

Fasting glucose as biomarker for weight loss success?

Pearl Toh, 20170621100001

Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!

Add-on isatuximab improves outlook for seniors with relapsed/refractory multiple myeloma

Jairia Dela Cruz, Yesterday

Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Original New Drug Application Approvals by US FDA (16 - 30 November 2018)

30 Nov 2018

New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Regional anaesthesia-analgesia offers little in terms of breast cancer recurrence risk

30 Oct 2019

Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.